

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 June 2025 (26.06.2025)



(10) International Publication Number
WO 2025/133197 A3

(51) International Patent Classification:

C12N 15/67 (2006.01) A61K 39/00 (2006.01)
A61K 38/00 (2006.01)

(21) International Application Number:

PCT/EP2024/088012

(22) International Filing Date:

20 December 2024 (20.12.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

23219955.4 22 December 2023 (22.12.2023) EP

(71) Applicant: **ETHERNA IMMUNOTHERAPIES NV**
[BE/BE]; Galileilaan 19, 2845 Niel (BE).

(72) Inventors: **BAUER, Lubos. HEIRMAN, Carlo. CHALLIS, Phillip.**

(74) Agent: **ARNOLD & SIEDSMA**; Bezuidenhoutseweg 57,
2594 AC THE HAGUE (NL).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(88) Date of publication of the international search report:

07 August 2025 (07.08.2025)

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: POLYNUCLEOTIDES COMPRISING 5'UTR - 3' UTR COMBINATIONS AND USE THEREOF

(57) Abstract: The present invention relates to the field of artificial polynucleotides and in particular to RNA polynucleotides comprising specific 5'UTR - 3'UTR gene combinations. Provided herein is an RNA polynucleotide comprising at least one 5'UTR element selected from a gene such as ANXA1, E. Coli enolase, RPS14, RPS25, or TCV and at least one 3'UTR selected from a gene such as HBA1, RPS29, Ube2d2a, or UBL5. The invention further relates to a pharmaceutical composition comprising one or more RNA polynucleotides according to the invention and a method of inducing an enhanced immune response in a subject using said RNA polynucleotides or pharmaceutical composition.



WO 2025/133197 A3